Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000-2012)

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jan 21

PMID 26787510

Citations 19

Authors

Gemma Binefa

Montse Garcia

Nuria Mila

Esteve Fernandez

Francisco Rodriguez-Moranta

Nuria Gonzalo

Llucia Benito

Ana Clopes

Jordi Guardiola

Victor Moreno

Affiliations

Soon will be listed here.

Abstract

Effective quality assurance is essential in any screening programme. This article provides a unique insight into key quality indicators of five rounds of the first population-based colorectal cancer screening programme implemented in Spain (2000-2012), providing the results according to the type of screening (prevalent or first screen and incident or subsequent screen) and test (guaiac or immunochemical). The total crude participation rate increased from 17.2% (11,011) in the first round to 35.9% (22,988) in the last one. Rescreening rate was very high (88.6% in the fifth round). Positivity rate was superior with the faecal immunochemical test (6.2%) than with the guaiac-based test (0.7%) (p < 0.0001) and detection rates were also better with the immunochemical test. The most significant rise in detection rate was observed for high risk adenoma in men (45.5 per 1,000 screened). Most cancers were diagnosed at an early stage (61.4%) and there was a statistically significant difference between those detected in first or subsequent screening (52.6% and 70.0% respectively; p = 0.024). The availability of these results substantially improves data comparisons and the exchange of experience between screening programmes.

Citing Articles

Diet Impacts on Gene Expression in Healthy Colon Tissue: Insights from the BarcUVa-Seq Study.

Obon-Santacana M, Moratalla-Navarro F, Guino E, Carreras-Torres R, Diez-Obrero V, Bars-Cortina D Nutrients. 2024; 16(18).

PMID: 39339731 PMC: 11434945. DOI: 10.3390/nu16183131.

Adherence to follow-up and resource use after abnormal FIT-screening: Evaluation of the Danish colorectal cancer screening program.

Jorgensen S, Larsen P, Erichsen R, Andersen B, Rebolj M, Njor S Endosc Int Open. 2024; 12(5):E649-E658.

PMID: 38707595 PMC: 11068436. DOI: 10.1055/a-2297-9622.

Test performance metrics for breast, cervical, colon, and lung cancer screening: a systematic review.

Selby K, Sedki M, Levine E, Kamineni A, Green B, Vachani A J Natl Cancer Inst. 2023; 115(4):375-384.

PMID: 36752508 PMC: 10086636. DOI: 10.1093/jnci/djad028.

Computer-aided diagnosis for optical diagnosis of diminutive colorectal polyps including sessile serrated lesions: a real-time comparison with screening endoscopists.

Houwen B, Hazewinkel Y, Giotis I, Vleugels J, Mostafavi N, van Putten P Endoscopy. 2023; 55(8):756-765.

PMID: 36623839 PMC: 10374350. DOI: 10.1055/a-2009-3990.

Meta-Analysis and Validation of a Colorectal Cancer Risk Prediction Model Using Deep Sequenced Fecal Metagenomes.

Obon-Santacana M, Mas-Lloret J, Bars-Cortina D, Criado-Mesas L, Carreras-Torres R, Diez-Villanueva A Cancers (Basel). 2022; 14(17).

PMID: 36077748 PMC: 9454621. DOI: 10.3390/cancers14174214.

References

Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6):1541-9. DOI: 10.1111/j.1572-0241.2008.01875.x. View

Barrett B, McKenna P . Communicating benefits and risks of screening for prostate, colon, and breast cancer. Fam Med. 2011; 43(4):248-53. View

Moran Sanchez S, Torrella E, Esteban Delgado P, Banos Madrid R, Garcia A, Ono A . Colonoscopy quality assessment. Rev Esp Enferm Dig. 2009; 101(2):107-12, 112-6. DOI: 10.4321/s1130-01082009000200004. View

Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E . Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol. 2009; 104(4):933-8. DOI: 10.1038/ajg.2009.14. View

Hol L, van Leerdam M, van Ballegooijen M, van Vuuren A, van Dekken H, Reijerink J . Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2009; 59(1):62-8. DOI: 10.1136/gut.2009.177089. View

Berchi C, Guittet L, Bouvier V, Launoy G . Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care. 2010; 26(1):48-53. DOI: 10.1017/S0266462309990808. View

Haug U, Hundt S, Brenner H . Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2009; 105(3):682-90. DOI: 10.1038/ajg.2009.668. View

Guittet L, Guillaume E, Levillain R, Beley P, Tichet J, Lantieri O . Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2011; 20(7):1492-501. DOI: 10.1158/1055-9965.EPI-10-0594. View

Guittet L, Bailly L, Bouvier V, Launoy G . Indirect comparison of two quantitative immunochemical faecal occult blood tests in a population with average colorectal cancer risk. J Med Screen. 2011; 18(2):76-81. DOI: 10.1258/jms.2011.011012. View

10.

Moss S, Campbell C, Melia J, Coleman D, Smith S, Parker R . Performance measures in three rounds of the English bowel cancer screening pilot. Gut. 2011; 61(1):101-7. PMC: 3230830. DOI: 10.1136/gut.2010.236430. View

11.

Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S . Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev. 2004; 13(1):19-26. DOI: 10.1097/00008469-200402000-00004. View

12.

Arbyn M, Van Oyen H, Lynge E, Micksche M, Faivre J, Jordan J . European Commission's proposal for a council recommendation on cancer screening. BMJ. 2003; 327(7409):289-90. PMC: 1126676. DOI: 10.1136/bmj.327.7409.289-b. View

13.

van Roon A, Hol L, van Vuuren A, Francke J, Ouwendijk M, Heijens A . Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol. 2011; 107(1):99-107. DOI: 10.1038/ajg.2011.396. View

14.

Faivre J, Dancourt V, Lejeune C, Tazi M, Lamour J, Gerard D . Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004; 126(7):1674-80. DOI: 10.1053/j.gastro.2004.02.018. View

15.

Kahi C, Imperiale T . Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004; 117(11):837-41. DOI: 10.1016/j.amjmed.2004.05.028. View

16.

Rex D, Petrini J, Baron T, Chak A, Cohen J, Deal S . Quality indicators for colonoscopy. Am J Gastroenterol. 2006; 101(4):873-85. DOI: 10.1111/j.1572-0241.2006.00673.x. View

17.

Bressler B, Paszat L, Chen Z, Rothwell D, Vinden C, Rabeneck L . Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007; 132(1):96-102. DOI: 10.1053/j.gastro.2006.10.027. View

18.

Guittet L, Bouvier V, Mariotte N, Vallee J, Arsene D, Boutreux S . Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2006; 56(2):210-4. PMC: 1856766. DOI: 10.1136/gut.2006.101428. View

19.

Lieberman D, Nadel M, Smith R, Atkin W, Duggirala S, Fletcher R . Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007; 65(6):757-66. DOI: 10.1016/j.gie.2006.12.055. View

20.

Peris M, Espinas J, Munoz L, Navarro M, Binefa G, Borras J . Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007; 14(2):81-6. DOI: 10.1258/096914107781261936. View